Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions
- PMID: 11851731
- DOI: 10.1046/j.1468-1331.2001.00035.x
Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions
Abstract
Botulinum toxin type A is an important therapeutic agent for the treatment of movement and other disorders. As the clinical uses of botulinum toxin type A expand, it is increasingly important to understand the biochemical and pharmacological actions of this toxin, as well as those of other botulinum toxin serotypes (B-G). Botulinum neurotoxin serotypes exhibit differences in neurotoxin complex protein size, percentage of neurotoxin in the activated or nicked form, intracellular protein target, and potency. These properties differ even between preparations that contain the same botulinum toxin serotype due to variations in product formulations. As demonstrated in preclinical and clinical studies, these differences result in a unique combination of efficacy, duration of action, safety, and antigenic potential for each botulinum neurotoxin preparation.
Similar articles
-
Pharmacology and immunology of botulinum toxin serotypes.J Neurol. 2001 Apr;248 Suppl 1:3-10. doi: 10.1007/pl00007816. J Neurol. 2001. PMID: 11357237 Review.
-
Botulinum toxin type B (Myobloc): pharmacology and biochemistry.Clin Dermatol. 2004 Jan-Feb;22(1):23-8. doi: 10.1016/j.clindermatol.2003.12.027. Clin Dermatol. 2004. PMID: 15158541 Review.
-
Botulinum toxin and spasticity.J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):143-7. doi: 10.1136/jnnp.69.2.143. J Neurol Neurosurg Psychiatry. 2000. PMID: 10896682 Free PMC article. No abstract available.
-
Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.Am J Clin Dermatol. 2011 Dec 1;12(6):377-88. doi: 10.2165/11592100-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21877763 Review.
-
Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology.Dis Mon. 2002 May;48(5):367-83. doi: 10.1053/mda.2001.24421. Dis Mon. 2002. PMID: 12195266 Review.
Cited by
-
Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo.Mol Ther Methods Clin Dev. 2014 Oct 1;1:14046. doi: 10.1038/mtm.2014.46. eCollection 2014. Mol Ther Methods Clin Dev. 2014. PMID: 26015984 Free PMC article.
-
Current and Emerging Medical Therapies for Primary Hyperhidrosis.Dermatol Ther (Heidelb). 2017 Mar;7(1):25-36. doi: 10.1007/s13555-016-0148-z. Epub 2016 Oct 27. Dermatol Ther (Heidelb). 2017. PMID: 27787745 Free PMC article. Review.
-
Exploring strategies to prevent post-lobectomy space: transient diaphragmatic paralysis using Botulinum toxin type A (BTX-A).Int Semin Surg Oncol. 2005 Oct 19;2:21. doi: 10.1186/1477-7800-2-21. Int Semin Surg Oncol. 2005. PMID: 16236161 Free PMC article.
-
Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure.Toxins (Basel). 2022 Jan 6;14(1):44. doi: 10.3390/toxins14010044. Toxins (Basel). 2022. PMID: 35051021 Free PMC article.
-
Temporary Botulinum Immobilization of Residuum Muscles for Facilitation of the Initial Ingrowth of Skin to the Porous Skin and Bone Integrated Pylon in the Technology of Direct Skeletal Attachment: Large Animal Model.Front Rehabil Sci. 2022 Mar;3:758238. doi: 10.3389/fresc.2022.758238. Epub 2022 Mar 3. Front Rehabil Sci. 2022. PMID: 35891709 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials